We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+40.06%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$164M
Cap. Flow
+$47.9M
Cap. Flow %
3.88%
Top 10 Hldgs %
53.52%
Holding
82
New
29
Increased
10
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49M
2
IMCR icon
Immunocore
IMCR
+$34.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.7M
4
SLN
Silence Therapeutics
SLN
+$23.4M
5
ADVM
Adverum Biotechnologies
ADVM
+$22.8M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
ARGX icon
argenx
ARGX
+$55.2M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$35.3M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$29.9M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
51
Boundless Bio
BOLD
$55.7M
$2.85M 0.23%
+200,000
New +$2.85M
TRML
52
DELISTED
Tourmaline Bio
TRML
$2.27M 0.18%
99,208
-185,164
-65% -$6.53M
CMPS
53
Compass Pathways
CMPS
$1.47B
$1.81M 0.15%
257,980
-242,020
-48% -$2.44M
IOBT
54
DELISTED
IO Biotech
IOBT
$854K 0.07%
493,827
– –
IMUX icon
55
Immunic
IMUX
$178M
$556K 0.05%
42,118
– –
CYPH
56
Cypherpunk Technologies Inc
CYPH
$64M
$105K 0.01%
+39,500
New +$118K
NUVB.WS
57
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$22.7K ﹤0.01%
66,666
– –
APLS
58
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,000,000
Closed -$59.9M
ARGX icon
59
argenx
ARGX
$55.2B
– –
-145,000
Closed -$55.2M
DCTH icon
60
Delcath Systems
DCTH
$400M
– –
-300,000
Closed -$1.25M
EWTX icon
61
Edgewise Therapeutics
EWTX
$4.28B
– –
-950,000
Closed -$10.4M
FULC icon
62
Fulcrum Therapeutics
FULC
$241M
– –
-1,200,000
Closed -$10.7M
IOVA icon
63
CALL
Iovance Biotherapeutics
IOVA
$2.04B
– –
-1,000,000
Closed -$8.13M
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$6.23B
– –
-150,000
Closed -$2.63M
MLTX icon
65
MoonLake Immunotherapeutics
MLTX
$1.56B
– –
-150,000
Closed -$9.06M
RCUS icon
66
Arcus Biosciences
RCUS
$3.33B
– –
-325,000
Closed -$6.21M
RNAM
67
DELISTED
Avidity Biosciences
RNAM
– –
-775,000
Closed -$7.01M
RPTX
68
DELISTED
Repare Therapeutics
RPTX
– –
-600,000
Closed -$4.38M
RVMD icon
69
Revolution Medicines
RVMD
$38.5B
– –
-350,000
Closed -$10M
SLRN
70
DELISTED
ACELYRIN
SLRN
– –
-1,250,000
Closed -$9.32M
VTYX
71
DELISTED
Ventyx Biosciences
VTYX
– –
-2,000,000
Closed -$4.94M
XENE icon
72
Xenon Pharmaceuticals
XENE
$6.1B
– –
-150,000
Closed -$6.91M
ZNTL icon
73
CALL
Zentalis Pharmaceuticals
ZNTL
$332M
– –
-500,000
Closed -$7.58M
MORF
74
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-200,000
Closed -$5.78M
MOR
75
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-1,000,000
Closed -$9.9M
1 2
3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2024 Portfolio in Review

As of Q1 2024, Logos Global Management held 82 positions worth $1.24B, up 15% from $1.07B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $47.9M of net new capital in Q1 2024, opening 29 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 400,000 shares worth $51.8M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $118M trimmed.

  • Logos Global Management's largest Q1 2024 buy was Sarepta Therapeutics: 400,000 shares worth $51.8M.
  • Logos Global Management added most to Immunocore in Q1 2024, an estimated $34.3M increase.
  • Logos Global Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $118M.
  • Logos Global Management fully exited argenx in Q1 2024, selling an estimated $55.2M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q1 2024.
  • Logos Global Management opened 29 new positions and closed 25 in Q1 2024.
  • Logos Global Management's portfolio value rose 15% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.